Meaningful survival benefit for single lung transplantation in IPF patients over 65 years of age.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that results in progressive respiratory failure and death. Antifibrotic therapy has been shown to slow disease progression [1, 2]. For many patients [3], lung transplantation is the only intervention recognised to provide significant survival benefit [4]. IPF commonly affects older patients, with the median age at diagnosis of 66 years old [5]. Without transplantation the median survival from diagnosis is 2–4 years [5]. However, registry data indicates impaired outcomes following lung transplantation for older patients [6]. These data have prompted many centres in Europe to avoid offering transplantation to older IPF patients. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Riddell has nothing to disclose. Conflict of interest: Dr. Kleinerova has nothing to disclose. Conflict of interest: Ms. Eaton has nothing to disclose. Conflict of interest: Prof. Healy has nothing to disclose. Conflict of interest: Mr. Javadpour has nothing to disclose. Conflict of interest: Prof. McCarthy has nothing to disclose. Conflict of interest: Mr. Nolke has nothing to disclose. Conflict of interest: Prof. Redmond has nothing to disclose. Conflict of interest: Prof. Egan has nothing to disclose.